New World monkey efficacy trials for malaria vaccine development: critical path or detour?
about
The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.Erythrocyte binding protein PfRH5 polymorphisms determine species-specific pathways of Plasmodium falciparum invasionAntibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels.
P2860
New World monkey efficacy trials for malaria vaccine development: critical path or detour?
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
New World monkey efficacy tria ...... ment: critical path or detour?
@en
New World monkey efficacy tria ...... ment: critical path or detour?
@nl
type
label
New World monkey efficacy tria ...... ment: critical path or detour?
@en
New World monkey efficacy tria ...... ment: critical path or detour?
@nl
prefLabel
New World monkey efficacy tria ...... ment: critical path or detour?
@en
New World monkey efficacy tria ...... ment: critical path or detour?
@nl
P2093
P1476
New World monkey efficacy tria ...... ment: critical path or detour?
@en
P2093
P304
P356
10.1016/S1471-4922(01)02012-8
P577
2001-09-01T00:00:00Z